BioVersys AG (CHIX:BIOVZ) Net Margin %: -1,352.50% (As of Dec. 2025)


CHIX:BIOVZ BioVersys AG CHIX:BIOVZ
14 GF Score
Price CHF27.10
View Full Analysis

What is BioVersys AG Net Margin %?

BioVersys AG CHIX:BIOVZ 14 Net Margin % is -1,352.50% as of Dec. 2025. GuruFocus rates CHIX:BIOVZ with a GF Score™ of 14/100. Among 938 Biotechnology companies, BioVersys AG ranks worse than 86.03% on this metric.

Net margin is calculated as Net Income divided by its Revenue. BioVersys AG's Net Income for the six months ended in Dec. 2025 was CHF-10.82 Mil. BioVersys AG's Revenue for the six months ended in Dec. 2025 was CHF0.80 Mil. Therefore, BioVersys AG's net margin for the quarter that ended in Dec. 2025 was -1,352.50%.

The historical rank and industry rank for BioVersys AG's Net Margin % or its related term are showing as below:

CHIX:BIOVz' s Net Margin % Range Over the Past 10 Years
Min: -2728.75   Med: -2728.75   Max: -2728.75
Current: -2728.75

CHIX:BIOVz's Net Margin % is ranked worse than
86.03% of 938 companies
in the Biotechnology industry
Industry Median: -88.295 vs CHIX:BIOVz: -2728.75

BioVersys AG  (CHIX:BIOVz) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

BioVersys AG Net Margin % Related Terms

BioVersys AG Net Margin % Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Net Margin % Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Net Margin %
0.00 -2,728.75

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Net Margin % 0.00 0.00 0.00 -1,352.50

CHIX:BIOVZ vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, BioVersys AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's Net Margin % distribution charts can be found below:

* The bar in red indicates where BioVersys AG's Net Margin % falls into.


CHIX:BIOVZ
14GF Score
BioVersys AG CHIX:BIOVZ
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

BioVersys AG's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-21.83/0.8
=-2,728.75 %

BioVersys AG's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-10.82/0.8
=-1,352.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -1,352.50% mean?
BioVersys AG (CHIX:BIOVZ) has a Net Margin % of -1,352.50% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #807 out of 938 companies in the Biotechnology industry, placing it in the top 86%.
Is BioVersys AG's Net Margin % too high?
BioVersys AG's current Net Margin % is -1,352.50%. Based on the distribution chart, BioVersys AG ranks #807 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #807 out of 938 companies for Net Margin %. This places BioVersys AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioVersys AG and its competitors. BioVersys AG's current Net Margin % is -1,352.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (CHIX:BIOVZ) has a current Net Margin % of -1,352.50%. The current Net Margin % is -1,352.50%. BioVersys AG's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioVersys AG (CHIX:BIOVZ), the current Net Margin % is -1,352.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges W33:GermanyBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
14GF Score

Get the complete analysis for CHIX:BIOVZ

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.10
Price